Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2019

Pemafibrate: promising effects in a mouse model of retinopathy

Results from this preclinical study suggest that pemafibrate, a novel SPPARM╬▒ (Selective Peroxisome Proliferator-Activated Receptor Alpha Modulator), may prevent pathological neovascularization in this mouse model of retinopathy. Using an oxygen-induced retinopathy model, researchers treated the mice with vehicle, pemafibrate or fenofibrate by oral gavage. Administration of pemafibrate, but not fenofibrate, significantly reduced pathological angiogenesis in this model. After pemafibrate dosage, there was upregulation of fibroblast growth factor 21 (FGF21), together with reductions in retinal hypoxia-inducible factor-1╬▒ and vascular endothelial growth factor A. These preliminary data warrant further study.
Pemafibrate prevents retinal pathological neovascularization by increasing FGF21 level in a murine oxygen-induced retinopathy model.

Tomita Y, Ozawa N, Miwa Y, et al